US 11,684,665 B2
Method for producing RNA molecule compositions
Tilmann Roos, Kusterdingen (DE); Martin Kunze, Rottenburg (DE); Benyamin Yazdan Panah, Tübingen (DE); Salih Yilmaz, Biberach an der Riss (DE); and Markus Conzelmann, Tübingen (DE)
Assigned to CureVac SE, Tübingen (DE)
Appl. No. 16/63,999
Filed by CureVac SE, Tübingen (DE)
PCT Filed Dec. 22, 2016, PCT No. PCT/EP2016/082487
§ 371(c)(1), (2) Date Jun. 19, 2018,
PCT Pub. No. WO2017/109134, PCT Pub. Date Jun. 29, 2017.
Claims priority of application No. PCT/EP2015/081000 (WO), filed on Dec. 22, 2015.
Prior Publication US 2019/0083602 A1, Mar. 21, 2019
Int. Cl. A61K 39/12 (2006.01); C12Q 1/68 (2018.01); C07K 14/005 (2006.01); C12Q 1/6844 (2018.01); A61P 21/00 (2006.01); A61P 31/00 (2006.01); A61P 39/00 (2006.01); C12N 15/10 (2006.01); C40B 40/02 (2006.01); C40B 40/08 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01); C40B 10/00 (2006.01)
CPC A61K 39/12 (2013.01) [A61P 21/00 (2018.01); A61P 31/00 (2018.01); A61P 39/00 (2018.01); C07K 14/005 (2013.01); C12N 15/1024 (2013.01); C12Q 1/6844 (2013.01); C40B 40/02 (2013.01); C40B 40/08 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C12N 2760/16111 (2013.01); C12N 2760/16122 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16222 (2013.01); C12N 2760/16234 (2013.01); C40B 10/00 (2013.01); Y02A 50/30 (2018.01)] 25 Claims
 
1. A method for producing a ribonucleic acid (RNA) pharmaceutical composition comprising at least two different RNA molecule species, the method comprising the following steps:
I) performing simultaneous RNA in vitro transcription of a mixture of at least two different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel, wherein each of the at least two different DNA molecule species encode the at least two different RNA molecule species thereby generating the at least two different RNA molecule species;
II) obtaining an RNA molecule composition comprising the at least two different RNA molecule species generated in step I);
III) purifying the RNA from the RNA molecule composition; and
IV) formulating the at least two different RNA molecule species in a pharmaceutical formulation to produce the RNA pharmaceutical composition,
wherein the at least two different RNA molecules vary in length from each other by no more than 100 nucleotides and wherein the amounts of each of the at least two different RNA molecules are not more than 20% different from each other in the RNA molecule composition.